Blanche H. Mavromatis
Expertise in
46
conditions

Dr. Blanche H. Mavromatis

Oncology
12500 Willowbrook Road, 
Cumberland, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Referral may be required
Before you request
Expertise in
46
conditions
12500 Willowbrook Road, 
Cumberland, MD 

Overview

Blanche Mavromatis, MD, specializes in hematology oncology and is board certified in internal medicine by the American Board of Internal Medicine. Dr. Mavromatis completed her fellowship at Georgetown University Hospital, residency at Georgetown University Medical Center and medical degree from Thomas Jefferson University Medical College.

Dr. Mavromatis is highly rated in 46 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome.

Dr. Mavromatis is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 18 clinical trials. Dr. Mavromatis is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in DC

Board Certifications

American Board Of Internal Medicine

Fellowships

MedStar Georgetown University Hospital

Hospital Affiliations

Upmc Bedford Memorial
Potomac Valley Hospital
Garrett Regional Medical Center
Western Maryland Regional Medical Center
West Virginia University Hospitals, Inc

Languages Spoken

English
French
Greek

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Peak Health
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center at UPMC Western Maryland
12500 Willowbrook Road, Cumberland, MD 21502

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
View 9 Less Clinical Trials

9 Total Publications

COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.
COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.
Journal: JCO oncology advances
Published: September 01, 2026
Similar Doctors
Expertise in
57
conditions
Expertise in
57
conditions
Referral may be required

UPMC Western Maryland

12500 Willowbrook Rd, 
Cumberland, MD 
 (0.1 miles away)
240-964-7000
Languages Spoken:
English, Punjabi, Urdu
See accepted insurances
Accepting New Patients

Qamar Zaman is an Oncologist practicing medicine in Cumberland, Maryland. Dr. Zaman is highly rated in 57 conditions, according to our data. His clinical expertise encompasses Anal Cancer, Thrombocytopenia, Non-Hodgkin Lymphoma, Gastric Lymphoma, and Bone Marrow Aspiration. Dr. Zaman is currently accepting new patients.

Expertise in
59
conditions
Dr. Richard M. Ingram
Hematology | Oncology
Expertise in
59
conditions
Dr. Richard M. Ingram
Hematology | Oncology
Referral may be required

Shenandoah Oncology PC

400 Campus Blvd Ste 100, 
Winchester, VA 
 (44.3 miles away)
540-662-1108
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Ingram is a Hematologist and an Oncologist practicing medicine in Winchester, Virginia. Dr. Ingram is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Large-Cell Immunoblastic Lymphoma, and Colorectal Cancer. Dr. Ingram is currently accepting new patients.

Expertise in
42
conditions
Dr. Lee P. Resta
Hematology | Oncology
Expertise in
42
conditions
Dr. Lee P. Resta
Hematology | Oncology
Referral may be required

Shenandoah Oncology PC

400 Campus Blvd Ste 100, 
Winchester, VA 
 (44.3 miles away)
540-662-1108
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lee Resta is a Hematologist and an Oncologist practicing medicine in Winchester, Virginia. Dr. Resta is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Resta is currently accepting new patients.

Frequently Asked Questions about Dr. Blanche H. Mavromatis

How do I make an appointment with Dr. Blanche H. Mavromatis?

You can book an appointment with Dr. Blanche H. Mavromatis by calling their office at 240-860-6665. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Blanche H. Mavromatis a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Blanche H. Mavromatis is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Blanche H. Mavromatis specialize in?

While Dr. Blanche H. Mavromatis is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Chronic Lymphocytic Leukemia (CLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Blanche H. Mavromatis participate in research or clinical trials?

Yes. Dr. Blanche H. Mavromatis has published 9 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Blanche H. Mavromatis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Blanche H. Mavromatis accept my insurance?

Dr. Blanche H. Mavromatis accepts most major insurance plans, including Aetna and CareFirst. We recommend calling the office directly at 240-860-6665 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mavromatis's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 31 Advanced Conditions
    View All 76 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile